US · Basic Materials · Specialty Chemicals
EPS came in at 2.95 against a street estimate of 1.31 — a beat of 125.2%.
Analysts rate Albemarle Corp a hold (9 buy, 17 hold, 2 sell out of 28) with an average price target of $187.16.
| Fund | Stake |
|---|---|
| Capital World Investors | 8.34% |
| BlackRock Inc | 7.41% |
| Vanguard Capital Management, LLC | 6.50% |
| Vanguard Portfolio Management, LLC | 5.36% |
| State Street Corp | 4.43% |
| Geode Capital Management, LLC | 2.91% |
| Bank of America Corp | 2.52% |
| PRIMECAP Management Company | 2.26% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 | 2026-07-23 |
| Board / officer change · Q2 2026 | 2026-06-05 |
| Board / officer change · Q2 2026 | 2026-05-08 |
| Quarterly report · Q1 2026 | 2026-05-06 |
| Results announced · Q2 2026 | 2026-05-06 |
| Proxy statement · Q4 2025 | 2026-03-24 |
| Annual report FY2025 | 2026-02-11 |
| Quarterly report · Q3 2025 | 2025-11-05 |
Readable in the app.
| Announcement | Date |
|---|---|
| Albemarle acquires majority stake in Ketjen, forms joint venture partnership Albemarle Corporation is selling its Ketjen catalysts business to a purchaser backed by private equity firm KPS Capital Partners. The deal is valued at $800 million (minus adjustments for ca | 2025-10-27 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Albemarle Corp — free to start.
Google PlayApp StoreData updated 2026-08-05.